NNVC NanoViricides, Inc.
$1.48▲ +1.27%
Healthcare
Other
Volume 64.9K
Avg Volume (10D) 209.1K
Key Metrics & Fundamentals
Market Cap
$37.76M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.85 - 2.23
% vs 50 MA
11.31%
% vs 200 MA
13.51%
RSI-14
55.5
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.19
Free Cash Flow
-$2.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.09M
COGS
–
Operating Exp
$2.25M
Operating Income
-$2.25M
EBIT
-$2.25M
Pretax Income
-$2.22M
Net Income
-$2.22M
Price & Volume History
Loading chart…
Recent News
As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides
ACCESS Newswire · Oct 27, 2026 9:15 AM ET
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
ACCESS Newswire · Oct 20, 2026 8:45 AM ET
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
ACCESS Newswire · Oct 13, 2026 8:45 AM ET
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
ACCESS Newswire · Oct 6, 2026 8:45 AM ET
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
ACCESS Newswire · Oct 5, 2026 8:45 AM ET
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
ACCESS Newswire · Sep 29, 2026 8:45 AM ET
NanoViricides: Fiscal Q4 Earnings Snapshot
Associated Press · Sep 28, 2026 4:48 PM ET
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
ACCESS Newswire · Sep 28, 2026 8:45 AM ET
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
ACCESS Newswire · Sep 23, 2026 8:30 AM ET
These Biotech Stocks Are Cheap Based On 1 Fundamental Measure
Simply Wall St. · Sep 17, 2026 5:34 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NNVC's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.